Brixadi is a drug owned by Braeburn Inc. It is protected by 7 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 26, 2032. Details of Brixadi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10912772 | Opioid formulations |
Jul, 2032
(7 years from now) | Active |
| US11110084 | Opioid formulations |
Jul, 2032
(7 years from now) | Active |
| US9937164 | Opioid formulations |
Jul, 2032
(7 years from now) | Active |
| US11135215 | Opioid formulations |
Jul, 2032
(7 years from now) | Active |
| US8236292 | Liquid depot formulations |
Jan, 2027
(2 years from now) | Active |
| US8236755 | Opioid depot formulations |
Jul, 2026
(1 year, 8 months from now) | Active |
| US8545832 | Lipid depot formulations |
Jun, 2025
(6 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Brixadi's patents.
Latest Legal Activities on Brixadi's Patents
Given below is the list of recent legal activities going on the following patents of Brixadi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8236755 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8236292 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Oct, 2021 | US9937164 |
| Recordation of Patent Grant Mailed Critical | 05 Oct, 2021 | US11135215 |
| Patent Issue Date Used in PTA Calculation Critical | 05 Oct, 2021 | US11135215 |
| Email Notification Critical | 16 Sep, 2021 | US11135215 |
| Issue Notification Mailed Critical | 15 Sep, 2021 | US11135215 |
| Mail Response to 312 Amendment (PTO-271) Critical | 07 Sep, 2021 | US11135215 |
| Patent Issue Date Used in PTA Calculation Critical | 07 Sep, 2021 | US11110084 |
| Recordation of Patent Grant Mailed Critical | 07 Sep, 2021 | US11110084 |
FDA has granted several exclusivities to Brixadi. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Brixadi, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Brixadi.
Exclusivity Information
Brixadi holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Brixadi's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2026 |
US patents provide insights into the exclusivity only within the United States, but Brixadi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Brixadi's family patents as well as insights into ongoing legal events on those patents.
Brixadi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Brixadi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 26, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Brixadi Generic API suppliers:
Buprenorphine is the generic name for the brand Brixadi. 5 different companies have already filed for the generic of Brixadi, with Alvogen having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Brixadi's generic
Alternative Brands for Brixadi
Brixadi which is used for managing opioid addiction and withdrawal symptoms through buprenorphine maintenance therapy., has several other brand drugs using the same active ingredient (Buprenorphine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Bdsi |
| ||
| Indivior |
| ||
| Orexo Us Inc |
| ||
| Purdue Pharma Lp |
| ||
| Reacx Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Buprenorphine, Brixadi's active ingredient. Check the complete list of approved generic manufacturers for Brixadi
About Brixadi
Brixadi is a drug owned by Braeburn Inc. It is used for managing opioid addiction and withdrawal symptoms through buprenorphine maintenance therapy. Brixadi uses Buprenorphine as an active ingredient. Brixadi was launched by Braeburn in 2023.
Approval Date:
Brixadi was approved by FDA for market use on 23 May, 2023.
Active Ingredient:
Brixadi uses Buprenorphine as the active ingredient. Check out other Drugs and Companies using Buprenorphine ingredient
Treatment:
Brixadi is used for managing opioid addiction and withdrawal symptoms through buprenorphine maintenance therapy.
Dosage:
Brixadi is available in solution, extended release form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 24MG/0.48ML (50MG/ML) | SOLUTION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 128MG/0.36ML (356MG/ML) | SOLUTION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 96MG/0.27ML (356MG/ML) | SOLUTION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 64MG/0.18ML (356MG/ML) | SOLUTION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 32MG/0.64ML (50MG/ML) | SOLUTION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 16MG/0.32ML (50MG/ML) | SOLUTION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 8MG/0.16ML (50MG/ML) | SOLUTION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |